Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 2.110
Filtrar
1.
J Zoo Wildl Med ; 52(1): 117-125, 2021 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-33827168

RESUMO

The objective of this pilot study was to examine the histologic effects associated with three known sclerosing agents and their ability to induce fibrosis in the subcutaneous space between the cervicocephalic air sac and skin. In the future, these drugs may prove useful in treating birds experiencing cervicocephalic diverticula rupture. The agents used were 1% polidocanol, absolute ethanol, and doxycycline hyclate. Twelve healthy adult chickens (Gallus gallus domesticus) were used in this study. The chickens were randomly allocated into three groups denoting day of euthanasia (day 4, 7, or 14). On day 0, all agents were injected (0.2 ml) subcutaneously, in a four-point grid fashion, in both the cervical and pectoral region of each bird. After euthanasia, the skin and subcutaneous tissues corresponding to the injection sites were harvested for histologic assessment. Tissue sections were assessed for fibrosis and lymphocytic and histiocytic inflammation. A scoring system was established to rank sclerosing agents by fibrosing and inflammatory ability. In the cervical region of chickens, 1% polidocanol induced the greatest inflammatory changes by day 7. Data suggest that doxycycline hyclate may produce the greatest cutaneous and subcutaneous fibrosis overall among all groups of birds. No adverse reactions were associated with any injection. Sterile saline produced the least amount of inflammation when assessed with the scoring system. Further investigation is needed to determine the safety of injections of larger volume with these chemicals and whether these findings can be extrapolated to birds with disease.


Assuntos
Sacos Aéreos/patologia , Galinhas , Doxiciclina/farmacologia , Etanol/farmacologia , Polidocanol/farmacologia , Animais , Doxiciclina/administração & dosagem , Quimioterapia Combinada , Etanol/administração & dosagem , Fibrose/induzido quimicamente , Fibrose/veterinária , Histiócitos , Inflamação/induzido quimicamente , Inflamação/veterinária , Linfócitos , Projetos Piloto , Polidocanol/administração & dosagem , Doenças das Aves Domésticas/terapia , Ruptura/terapia , Ruptura/veterinária , Soluções Esclerosantes/administração & dosagem , Soluções Esclerosantes/uso terapêutico , Pele/efeitos dos fármacos , Pele/patologia
3.
AAPS PharmSciTech ; 22(3): 77, 2021 Feb 17.
Artigo em Inglês | MEDLINE | ID: mdl-33595740

RESUMO

Currently, periodontitis is treated by oral dosage forms (antibiotics) which shows systemic side effects and failed to reach the therapeutic concentration (above minimum inhibitory concentration, MIC) in the periodontal pocket. The present study aimed to overcome the above issues, by designing tailored doxycycline hyclate laden in situ gel by Poloxamer 407, chitosan, and polyethylene glycol 600. The in situ gel-forming system has attracted attention owing to its ability of sustained drug release above MIC, easy administration (syringeability), and high drug retention (localization) in the periodontal cavity. The Box-Behnken design (BBD) was used to tailor and optimize the concentration of Poloxamer 407 (X1 = 14.3%), chitosan (X2 = 0.58%), and polyethylene glycol 600 (X3 = 1.14%) to achieve sufficient syringeability (149 N), t90% (1105 min), and viscosity at non-physiological condition (512 cps) and physiological condition (5415 cps). The optimized in situ gel was clear and isotonic (RBCs test). The gelation temperature of the optimized in situ was 34 ± 1°C with sufficient mucoadhesive strength (26 ± 2 dyn/cm2), gel strength (29 ± 2 sec), and texture profile for periodontal application. The in vitro drug release studies showed sustain release from optimized in situ gel (24h) in comparison to marketed gel (7h). The antimicrobial activity (cup plate technique) of the in situ gel was equivalent to the marketed doxycycline gel, which suggests that the doxycycline hyclate retained its antimicrobial efficacy when formulated as in situ gelling system. In conclusion, BBD was effectively utilized to optimize in situ gel with minimum level of polymers to achieve the required characteristics of the in situ gel for sustaining drug delivery to treat periodontitis.


Assuntos
Antibacterianos/administração & dosagem , Doxiciclina/administração & dosagem , Sistemas de Liberação de Medicamentos , Periodontite/tratamento farmacológico , Quitosana/química , Doxiciclina/química , Sistemas de Liberação de Medicamentos/métodos , Liberação Controlada de Fármacos , Géis/administração & dosagem , Humanos , Poloxâmero/química , Polímeros/química
4.
ACS Appl Mater Interfaces ; 13(2): 2371-2381, 2021 Jan 20.
Artigo em Inglês | MEDLINE | ID: mdl-33404209

RESUMO

This work describes the preparation and characterization of printed biodegradable polymer (polylactic acid) capsules made in two different shapes: pyramid and rectangular capsules about 1 and 11 µm in size. Obtained core-shell capsules are described in terms of their morphology, loading efficiency, cargo release profile, cell cytotoxicity, and cell uptake. Both types of capsules showed monodisperse size and shape distribution and were found to provide sufficient stability to encapsulate small water-soluble molecules and to retain them for several days and ability for intracellular delivery. Capsules of 1 µm size can be internalized by HeLa cells without causing any toxicity effect. Printed capsules show unique characteristics compared with other drug delivery systems such as a wide range of possible cargoes, triggered release mechanism, and highly controllable shape and size.


Assuntos
Composição de Medicamentos/métodos , Sistemas de Liberação de Medicamentos , Poliésteres/química , Animais , Antibacterianos/administração & dosagem , Antibacterianos/farmacocinética , Cápsulas/química , Linhagem Celular , Doxiciclina/administração & dosagem , Doxiciclina/farmacocinética , Composição de Medicamentos/instrumentação , Desenho de Equipamento , Células HeLa , Humanos , Camundongos , Tamanho da Partícula , Impressão Tridimensional/instrumentação
5.
BMJ Case Rep ; 14(1)2021 Jan 18.
Artigo em Inglês | MEDLINE | ID: mdl-33462032

RESUMO

Morel-Lavallée lesion is a chronic, recurrent collection of serous fluid in the soft tissues and usually occurs following injury. The most common sites are thigh, hip and pelvic region. This presents as a local or diffuse swelling and may cause discomfort to the patient besides being a potential site for bacterial contamination. So, early diagnosis and timely management is crucial for an early and successful outcome. The investigation modality of choice for diagnosis of these lesions is MRI. Definitive management ranges from percutaneous aspiration with or without sclerotherapy to open debridement and irrigation. Although recurrences are common with conservative management, it can be minimised with judicious use of sclerotherapy.


Assuntos
Antibacterianos/administração & dosagem , Doxiciclina/administração & dosagem , Escleroterapia , Seroma/diagnóstico , Seroma/etiologia , Coxa da Perna/lesões , Acidentes por Quedas , Desbridamento , Drenagem , Feminino , Humanos , Seroma/terapia , Adulto Jovem
6.
Av. odontoestomatol ; 36(3): 161-173, sept.-dic. 2020. graf
Artigo em Espanhol | IBECS | ID: ibc-197415

RESUMO

INTRODUCCIÓN: la sífilis es una infección bacteriana, que se puede transmitir por contacto sexual o de forma congénita. Esta enfermedad consta de tres estadios, en los cuales se pueden dar diferentes manifestaciones orales. MATERIAL Y MÉTODO: se realizó una búsqueda en la base de datos PubMed, utilizándose como palabras clave: "sexually transmitted diseases", "venereal diseases", "syphilis", "primary syphilis", "secondary syphilis", "tertiary syphilis", "oral manifestations", "oral lesions". Como criterios de inclusión se emplearon: series de casos, estudios en los que el tema principal fueran las manifestaciones orales de la sífilis y trabajos en inglés y español. No hubo restricción por fecha. RESULTADOS: se seleccionaron un total de 18 artículos, la N total de pacientes fue de 201. El 10,05% padecía sífilis primaria, el 52,76% sífilis secundaria y el 36, 68% sífilis terciaria. Las lesiones orales predominantes de la sífilis primaria fueron úlceras, inflamación, chancro sifilítico; en la sífilis secundaria se apreciaban placas mucosas, lesiones eritematosas, inflamación, lesiones papulares, lesiones maculares, lesiones erosivas; en la sífilis terciaria aparecen gomas sifilíticos, lesiones leucoplásicas y atrofia lingual. DISCUSIÓN: la sífilis es una infección bacteriana que puede simular diversas enfermedades, es muy importante tenerla en cuenta a la hora de realizar el diagnóstico diferencial de diversas lesiones orales, sobre todo aquellas que se presentan de forma ulcerosa, indurada y asintomática


INTRODUCTION: syphilis is a bacterial infection, which is transmitted by sexual contact or congenitally. This disease develops in three stages, in which different oral manifestations can occur. MATERIAL AND METHOD: a search was made in the PubMed database, using as keywords: "sexually transmitted diseases", "venereal diseases", "syphilis", "primary syphilis", "secondary syphilis", "tertiary syphilis", "Oral manifestations", "oral lesions". The inclusion criteria were: case series, studies in which the main theme was the oral manifestations of syphilis and works in English and Spanish. There was no restriction by date. RESULTS: a total of 18 articles were selected, the total sample of patients was 201. 10.05% had primary syphilis, 52.76% secondary syphilis and 36, 68% tertiary syphilis. The predominant oral lesions of primary syphilis were ulcers, inflammation, syphilitic chancre; in secondary syphilis there were mucous patches, erythematous lesions, inflammation, papular lesions, macular lesions, erosive lesions; in tertiary syphilis, syphilitic gums, leukoplastic lesions and lingual atrophy. DISCUSSION: Syphilis is a bacterial infection that can simulate various diseases, it is very important to take it into account when making the differential diagnosis of various oral lesions, especially those that occur in an ulcerative, indurated and asymptomatic form


Assuntos
Humanos , Sífilis/patologia , Sífilis/epidemiologia , Doenças da Boca/patologia , Sífilis/diagnóstico , Boca/lesões , Diagnóstico Diferencial , Penicilinas/administração & dosagem , Penicilina G Benzatina/administração & dosagem , Doxiciclina/administração & dosagem , Amoxicilina/administração & dosagem , Probenecid/administração & dosagem
7.
MMWR Morb Mortal Wkly Rep ; 69(50): 1911-1916, 2020 Dec 18.
Artigo em Inglês | MEDLINE | ID: mdl-33332296

RESUMO

Sexually transmitted infections (STIs) caused by the bacteria Neisseria gonorrhoeae (gonococcal infections) have increased 63% since 2014 and are a cause of sequelae including pelvic inflammatory disease, ectopic pregnancy, and infertility and can facilitate transmission of human immunodeficiency virus (HIV) (1,2). Effective treatment can prevent complications and transmission, but N. gonorrhoeae's ability to acquire antimicrobial resistance influences treatment recommendations and complicates control (3). In 2010, CDC recommended a single 250 mg intramuscular (IM) dose of ceftriaxone and a single 1 g oral dose of azithromycin for treatment of uncomplicated gonococcal infections of the cervix, urethra, and rectum as a strategy for preventing ceftriaxone resistance and treating possible coinfection with Chlamydia trachomatis (4). Increasing concern for antimicrobial stewardship and the potential impact of dual therapy on commensal organisms and concurrent pathogens (3), in conjunction with the continued low incidence of ceftriaxone resistance and the increased incidence of azithromycin resistance, has led to reevaluation of this recommendation. This report, which updates previous guidelines (5), recommends a single 500 mg IM dose of ceftriaxone for treatment of uncomplicated urogenital, anorectal, and pharyngeal gonorrhea. If chlamydial infection has not been excluded, concurrent treatment with doxycycline (100 mg orally twice a day for 7 days) is recommended. Continuing to monitor for emergence of ceftriaxone resistance through surveillance and health care providers' reporting of treatment failures is essential to ensuring continued efficacy of recommended regimens.


Assuntos
Gonorreia/tratamento farmacológico , Guias de Prática Clínica como Assunto , Administração Oral , Ceftriaxona/administração & dosagem , Centers for Disease Control and Prevention, U.S. , Infecções por Chlamydia/complicações , Infecções por Chlamydia/tratamento farmacológico , Chlamydia trachomatis , Coinfecção/tratamento farmacológico , Doxiciclina/administração & dosagem , Medicina Baseada em Evidências , Gonorreia/complicações , Humanos , Injeções Intramusculares , Estados Unidos
8.
Korean J Parasitol ; 58(5): 565-569, 2020 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-33202509

RESUMO

This report describes the first clinical case of a transfusion-associated Mycoplasma haemocanis infection in a dog in Korea. A 6-year-old male Maltese underwent a red blood cell transfusion for idiopathic immune-mediated hemolytic anemia. Eighteen days after the blood transfusion, the recipient's packed cell volume decreased and basophilic organisms were found on erythrocytes. A polymerase chain reaction and sequential analysis showed that both the donor dog and recipient dog had M. haemocanis. Six weeks after doxycycline administration, no organisms were detected and the recipient's anemia had improved.


Assuntos
Anemia Hemolítica Autoimune/terapia , Anemia Hemolítica Autoimune/veterinária , Transfusão de Sangue/veterinária , Doenças do Cão/terapia , Doenças do Cão/transmissão , Doxiciclina/administração & dosagem , Infecções por Mycoplasma/transmissão , Infecções por Mycoplasma/veterinária , Mycoplasma , Reação Transfusional/microbiologia , Reação Transfusional/veterinária , Animais , Doenças do Cão/etiologia , Doenças do Cão/microbiologia , Cães , Masculino , Infecções por Mycoplasma/tratamento farmacológico , Infecções por Mycoplasma/microbiologia , República da Coreia , Resultado do Tratamento
9.
BMC Infect Dis ; 20(1): 826, 2020 Nov 11.
Artigo em Inglês | MEDLINE | ID: mdl-33176719

RESUMO

BACKGROUND: Human granulocytic anaplasmosis (HGA) is a tick-borne infectious disease caused by Anaplasma phagocytophilum. To date, there have been no reported cases of A. phagocytophilum infection found in both the biting tick and the patient following a tick bite. CASE PRESENTATION: An 81-year-old woman presented with fever following a tick bite, with the tick still intact on her body. The patient was diagnosed with HGA. The tick was identified as Ixodes nipponensis by morphological and molecular biological detection methods targeting the 16S rRNA gene. The patient's blood was cultured after inoculation into the human promyelocytic leukemia cell line HL-60. A. phagocytophilum growth was confirmed via culture and isolation. A. phagocytophilum was identified in both the tick and the patient's blood by Anaplasma-specific groEL- and ankA-based nested polymerase chain reaction followed by sequencing. Moreover, a four-fold elevation in antibodies was observed in the patient's blood. CONCLUSION: We report a case of a patient diagnosed with HGA following admission for fever due to a tick bite. A. phagocytophilum was identified in both the tick and the patient, and A. phagocytophilum was successfully cultured. The present study suggests the need to investigate the possible incrimination of I. nipponensis as a vector for HGA in Korea.


Assuntos
Anaplasma phagocytophilum/genética , Anaplasmose/diagnóstico , Ixodes/microbiologia , Picadas de Carrapatos/microbiologia , Doenças Transmitidas por Carrapatos/diagnóstico , Idoso de 80 Anos ou mais , Anaplasma phagocytophilum/isolamento & purificação , Anaplasmose/tratamento farmacológico , Anaplasmose/microbiologia , Animais , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Doxiciclina/administração & dosagem , Doxiciclina/uso terapêutico , Feminino , Febre , Células HL-60 , Humanos , Reação em Cadeia da Polimerase , RNA Ribossômico 16S/genética , República da Coreia , Doenças Transmitidas por Carrapatos/tratamento farmacológico , Doenças Transmitidas por Carrapatos/microbiologia , Resultado do Tratamento
10.
BMJ Case Rep ; 13(11)2020 Nov 03.
Artigo em Inglês | MEDLINE | ID: mdl-33148588

RESUMO

Fever is a widely recognised presenting symptom of COVID-19. Consequently, other febrile illnesses may be difficult to distinguish from COVID-19-leading to delays in diagnosis and treatment. One such illness is murine typhus, a fleaborne illness with worldwide distribution caused by Rickettsia typhi It often presents with fever, headache and myalgia, all of which have been commonly reported with COVID-19. Although the disease is usually mild with a good prognosis, there have been reports of severe illness and death. I present a case of murine typhus in a young male who had 2 weeks of headaches and daily fevers during the COVID-19 pandemic. He was ultimately tested for murine typhus when his occupation as a dog trainer was queried, and he experienced resolution of symptoms after treatment with doxycycline. During this pandemic, clinicians must be vigilant of other febrile illnesses whose symptoms overlap with COVID-19.


Assuntos
Infecções por Coronavirus/diagnóstico , Doxiciclina/administração & dosagem , Febre/diagnóstico , Exposição Ocupacional/análise , Pneumonia Viral/diagnóstico , Rickettsia typhi/isolamento & purificação , Tifo Endêmico Transmitido por Pulgas , Adulto , Assistência Ambulatorial/métodos , Animais , Antibacterianos/administração & dosagem , Betacoronavirus , Diagnóstico Diferencial , Reservatórios de Doenças/microbiologia , Transmissão de Doença Infecciosa , Cães , Febre/etiologia , Humanos , Masculino , Pandemias , Resultado do Tratamento , Tifo Endêmico Transmitido por Pulgas/diagnóstico , Tifo Endêmico Transmitido por Pulgas/tratamento farmacológico , Tifo Endêmico Transmitido por Pulgas/microbiologia , Tifo Endêmico Transmitido por Pulgas/fisiopatologia
11.
Ther Adv Respir Dis ; 14: 1753466620951053, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32873175

RESUMO

Infection with novel SARS-CoV-2 carries significant morbidity and mortality in patients with pulmonary compromise, such as lung cancer, autoimmune disease, and pneumonia. For early stages of mild to moderate disease, care is entirely supportive.Antiviral drugs such as remdesivir may be of some benefit but are reserved for severe cases given limited availability and potential toxicity. Repurposing of safer, established medications that may have antiviral activity is a possible approach for treatment of earlier-stage disease. Tetracycline and its derivatives (e.g. doxycycline and minocycline) are nontraditional antibiotics with a well-established safety profile, potential efficacy against viral pathogens such as dengue fever and chikungunya, and may regulate pathways important in initial infection, replication, and systemic response to SARS-CoV-2. We present a series of four high-risk, symptomatic, COVID-19+ patients, with known pulmonary disease, treated with doxycycline with subsequent rapid clinical improvement. No safety issues were noted with use of doxycycline.Doxycycline is an attractive candidate as a repurposed drug in the treatment of COVID-19 infection, with an established safety profile, strong preclinical rationale, and compelling initial clinical experience described here.The reviews of this paper are available via the supplemental material section.


Assuntos
Adenocarcinoma de Pulmão/complicações , Infecções por Coronavirus/tratamento farmacológico , Doxiciclina/administração & dosagem , Pneumonia Viral/tratamento farmacológico , Doença Pulmonar Obstrutiva Crônica/complicações , Sarcoidose Pulmonar/complicações , Adenocarcinoma de Pulmão/diagnóstico , Adenocarcinoma de Pulmão/terapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Comorbidade , Infecções por Coronavirus/complicações , Infecções por Coronavirus/diagnóstico , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Multimorbidade , Pandemias , Pneumonia Viral/complicações , Pneumonia Viral/diagnóstico , Doença Pulmonar Obstrutiva Crônica/diagnóstico , Doença Pulmonar Obstrutiva Crônica/terapia , Medição de Risco , Amostragem , Sarcoidose Pulmonar/diagnóstico , Sarcoidose Pulmonar/terapia , Resultado do Tratamento
13.
BMC Infect Dis ; 20(1): 505, 2020 Jul 13.
Artigo em Inglês | MEDLINE | ID: mdl-32660552

RESUMO

BACKGROUND: Meningococcal meningitis (MM) is a life-threatening disease associated with approximately 10% case fatality rates and neurological sequelae in 10-20% of the cases. Recently, we have shown that the matrix metalloproteinase (MMP) inhibitor BB-94 reduced brain injury in a mouse model of MM. The present study aimed to assess whether doxycycline (DOX), a tetracycline that showed a neuroprotective effect as adjuvant therapy in experimental pneumococcal meningitis (PM), would also exert a beneficial effect when given as adjunctive therapy to ceftriaxone (CRO) in experimental MM. METHODS: BALB/c mice were infected by the intracisternal route with a group C Neisseria meningitidis strain. Eighteen h post infection (hpi), animals were randomised for treatment with CRO [100 mg/kg subcutaneously (s.c.)], CRO plus DOX (30 mg/kg s.c.) or saline (control s.c.). Antibiotic treatment was repeated 24 and 40 hpi. Mouse survival and clinical signs, bacterial counts in cerebella, brain damage, MMP-9 and cyto/chemokine levels were assessed 48 hpi. RESULTS: Analysis of bacterial load in cerebella indicated that CRO and CRO + DOX were equally effective at controlling meningococcal replication. No differences in survival were observed between mice treated with CRO (94.4%) or CRO + DOX (95.5%), (p > 0.05). Treatment with CRO + DOX significantly diminished both the number of cerebral hemorrhages (p = 0.029) and the amount of MMP-9 in the brain (p = 0.046) compared to untreated controls, but not to CRO-treated animals (p > 0.05). Levels of inflammatory markers in the brain of mice that received CRO or CRO + DOX were not significantly different (p > 0.05). Overall, there were no significant differences in the parameters assessed between the groups treated with CRO alone or CRO + DOX. CONCLUSIONS: Treatment with CRO + DOX showed similar bactericidal activity to CRO in vivo, suggesting no antagonist effect of DOX on CRO. Combined therapy significantly improved mouse survival and disease severity compared to untreated animals, but addition of DOX to CRO did not offer significant benefits over CRO monotherapy. In contrast to experimental PM, DOX has no adjunctive activity in experimental MM.


Assuntos
Antibacterianos/uso terapêutico , Ceftriaxona/uso terapêutico , Doxiciclina/uso terapêutico , Meningite Meningocócica/tratamento farmacológico , Neisseria meningitidis Sorogrupo C , Animais , Antibacterianos/administração & dosagem , Carga Bacteriana/efeitos dos fármacos , Ceftriaxona/administração & dosagem , Hemorragia Cerebral/tratamento farmacológico , Quimiocinas/análise , Quimiocinas/metabolismo , Modelos Animais de Doenças , Doxiciclina/administração & dosagem , Quimioterapia Combinada , Feminino , Humanos , Estimativa de Kaplan-Meier , Metaloproteinase 9 da Matriz/análise , Metaloproteinase 9 da Matriz/metabolismo , Meningite Meningocócica/mortalidade , Camundongos , Camundongos Endogâmicos BALB C , Distribuição Aleatória , Resultado do Tratamento
17.
Carbohydr Polym ; 237: 116163, 2020 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-32241426

RESUMO

A polyelectrolyte complex nanoparticle comprising chitosan (CS) and carboxymethyl chitosan (CMCS) was prepared (CS/CMCS-NPs) by ionic gelation, which was then used as a doxycycline carrier (Dox:CS/CMCS-NPs). The obtained CS/CMCS-NPs and Dox:CS/CMCS-NPs were characterized for various parameters and bacteriostatic ability against Porphyromonas gingivalis. The regulation of related genes and proteins of NLRP3 inflammasome and IL-1ß in human gingival fibroblasts (HGFs) was characterized by qRT-PCR, western blotting and ELISA. The results showed that Dox:CS/CMCS-NPs had an orderly morphology and an excellent cytocompatibility. P. gingivalis was strongly inhibited by Dox:CS/CMCS-NPs contrasted with control group. Dox:CS/CMCS-NPs effectively down-regulated both gene and protein levels of NLRP3 inflammasome and IL-1ß in HGFs. This study provides a new method for rational application of Dox in the clinical treatment of periodontal disease and a new direction for explaining the mechanism of action of Dox:CS/CMCS-NPs and more drug-carrying nanoparticles.


Assuntos
Antibacterianos/administração & dosagem , Quitosana/análogos & derivados , Doxiciclina/administração & dosagem , Inflamassomos/metabolismo , Proteína 3 que Contém Domínio de Pirina da Família NLR/metabolismo , Nanopartículas/administração & dosagem , Doenças Periodontais/metabolismo , Adolescente , Antibacterianos/química , Células Cultivadas , Quitosana/administração & dosagem , Quitosana/química , Doxiciclina/química , Fibroblastos/efeitos dos fármacos , Fibroblastos/metabolismo , Humanos , Inflamassomos/genética , Proteína 3 que Contém Domínio de Pirina da Família NLR/genética , Nanopartículas/química , Doenças Periodontais/genética , Porphyromonas gingivalis/efeitos dos fármacos , Porphyromonas gingivalis/crescimento & desenvolvimento
18.
Am J Otolaryngol ; 41(4): 102463, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32229044

RESUMO

Treatment of thoracic duct leaks can be very challenging. Intractable chlye leaks may require image-guided methods to increase the likelihood of treatment success. Near infra-red fluorescence is an easy-to-use nonionizing imaging method that has been described to detect thoracic duct leaks in open surgery or thoracoscopic interventions, yet no application to percutaneous sclerotherapy has been described. The authors suggest near infra-red fluorescence as a feasible and useful tool to guide percutaneous sclerotherapy.


Assuntos
Quilotórax/etiologia , Quilotórax/terapia , Imagem Óptica/métodos , Complicações Pós-Operatórias/terapia , Escleroterapia/métodos , Ducto Torácico/lesões , Idoso , Quilotórax/diagnóstico por imagem , Doxiciclina/administração & dosagem , Humanos , Masculino , Soluções Esclerosantes/administração & dosagem , Resultado do Tratamento
19.
Arq. bras. oftalmol ; 83(2): 109-112, Mar.-Apr. 2020. tab
Artigo em Inglês | LILACS | ID: biblio-1088962

RESUMO

ABSTRACT Purpose: To compare the impact of ocular changes between systemic treatment with doxycycline and low-dose oral isotretinoin in patients with moderate-to-severe papulopustular rosacea. Methods: Patients were randomized to receive either isotretinoin 0.3-0.4 mg/kg (group A) or doxycycline 100 mg/day (group B) for 16 weeks. Ocular symptoms were searched and evaluated, including best-corrected visual acuity (BCVA), Schirmer test, breakup time, rose bengal staining score, and meibomian gland dysfunction grading. The patients were retested at the end of treatment. Results: The present study included 39 patients (30 females and 9 males). Best-corrected visual acuity was > 20/30 in >90% of patients in both groups and did not change after treatment. After treatment, improvement in ocular symptoms and meibomian gland dysfunction was more pronounced in group B (p<0.05); the other parameters did not reach statistical significance. Conclusion: Doxycycline improved meibomian gland dysfunction, ocular symptoms, and ocular surface in patients with rosacea. Even though some patients experienced worsening meibomian gland dysfunction and symptoms, no subject experienced any serious complications after administration of low-dose isotretinoin.


RESUMO Objetivos: Comparar o impacto das alterações oculares entre o tratamento sistêmico de doxiciclina e isotretinoína em baixa dosagem em pacientes com rosácea papulopustulosa moderada a grave. Métodos: Os pacientes form randomizados para receber isotretinoína 0,3 a 0,4 mg/kg (grupo A) ou doxiciclina 100mg/dia (grupo B) por 16 semanas. Os sintomas oculares foram pesquisados e avaliados, incluindo melhor acuidade visual corrigida, teste de Schirmer, tempo de ruptura do filme lacrimal, coloração de rosa bengala e graduação da disfunção de glândula de Meibomius. Os pacientes foram novamente testados no final do tratamento. Resultados: O presente estudo incluiu 39 pacientes (30 mulheres e 9 homens). A melhor acuidade visual corrigida foi >20/30 em >90% dos pacientes em ambos os grupos e não se alterou após o tratamento. A melhora dos sintomas oculares e da disfunção de glândula de Meibomius foi mais pronunciada no grupo B (p<0,05) após o tratamento; as demais variáveis não atingiram significância estatística. Conclusão: A doxiciclina melhorou a disfunção de glândula de Meibomius, os sintomas oculares e a superfície ocular de pa cientes com rosácea. Mesmo que alguns pacientes tenham piorado a disfunção e os sintomas da glândula de Meibomius, nenhum indivíduo apresentou complicações graves após a admi nistração de baixas doses de isotretinoína.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Adulto Jovem , Isotretinoína/administração & dosagem , Doxiciclina/administração & dosagem , Rosácea/tratamento farmacológico , Fármacos Dermatológicos/administração & dosagem , Disfunção da Glândula Tarsal/tratamento farmacológico , Antibacterianos/administração & dosagem , Índice de Gravidade de Doença , Acuidade Visual , Administração Oral , Resultado do Tratamento , Rosácea/fisiopatologia , Olho/efeitos dos fármacos , Disfunção da Glândula Tarsal/fisiopatologia , Glândulas Tarsais/efeitos dos fármacos
20.
Drug Deliv ; 27(1): 449-459, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-32157918

RESUMO

Smart phase transformation systems@hard capsule (SPTS@hard capsule) based on lyotropic liquid crystalline (LLC) were developed for oral sustained release in this study. Doxycycline hydrochloride (DOXY) and meloxicam (MLX) were used as hydrophilic and hydrophobic model drug, respectively. Two systems were added with different additives, that is, gelucire 39/01, PEG 1000 and Tween 80 to adjust their melting point and release profiles. The phase transformation of these systems could be triggered by water as well as temperature. They could spontaneously transform into cubic phase or hexagonal phase when coming across with water, to achieve the 24 h sustained release profile. In addition, the obtained systems could switch between semisolid state and liquid state when temperature changed within room temperature and body temperature, which facilitated the phase transformation in gastrointestinal tract and during their encapsulation into hard capsules. LLC-based SPTS@hard capsule revealed potential for the industrialization of its oral administration on account of its drugs accommodation with different solubility, controllable release profile and simple preparation process.


Assuntos
Doxiciclina/química , Excipientes/química , Meloxicam/química , Cápsulas , Química Farmacêutica , Preparações de Ação Retardada , Doxiciclina/administração & dosagem , Liberação Controlada de Fármacos , Glicerídeos/química , Interações Hidrofóbicas e Hidrofílicas , Cristais Líquidos , Meloxicam/administração & dosagem , Transição de Fase , Polietilenoglicóis/química , Polissorbatos/química , Solubilidade , Temperatura , Temperatura de Transição , Água/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...